PRLR and neoplasm: Combined with PD-1 mAb, the best killing activity reached to 55% (Fig. 7b and c), which demonstrated blockade of PD-1 might enhance the PRLR-DbsAb-mediated cytotoxicity of against tumor cells with high level of PD-L1.